sr141716 has been researched along with Central Nervous System Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kyrou, I; Tsigos, C; Valsamakis, G | 1 |
1 review(s) available for sr141716 and Central Nervous System Disease
| Article | Year |
|---|---|
The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
Topics: Cannabinoid Receptor Modulators; Central Nervous System Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction | 2006 |
1 other study(ies) available for sr141716 and Central Nervous System Disease
| Article | Year |
|---|---|
[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoids; Central Nervous System; Central Nervous System Diseases; Drug Approval; Germany; Humans; Mental Disorders; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss | 2007 |